SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Sepsis, Pulmonary Inflammation and Fibrosis at the Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference 2025
SignaBlok will present groundbreaking positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and [read full press release…]